Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study. (PubMed, Medicina (Kaunas)) - Sep 27, 2026 - " Baseline mGPS is a simple, inexpensive, and independent prognostic biomarker in mRCC patients treated with second-line nivolumab, providing discriminatory information that may be complementary alongside IMDC risk stratification. Prospective validation in randomised trials is warranted."
Journal • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CRP
|
|
Ahmet Melih Arslan; Ahmet Ünsal; Faruk Recep Özalp; Gülhan Dinç; Hüseyin Salih Semiz; Mehmet Türker; Mehmet Uzun; Mustafa Erman; Mustafa Seyyar; Nadiye Sever; Nargiz Majidova Altunta?; Sedat Biter; Umut Kefeli
|